| P50 | author | Thomas F Baumert | Q88786090 |
| | Che C Colpitts | Q42320812 |
| P2860 | cites work | Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies | Q43041465 |
| | Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge | Q43048336 |
| | Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 |
| | Hepatitis C and liver transplantation | Q59098576 |
| | A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion | Q21089597 |
| | Binding of hepatitis C virus to CD81 | Q22004178 |
| | The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus | Q24307963 |
| | Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance | Q26781331 |
| | Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein | Q27333881 |
| | Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein | Q27470798 |
| | Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry | Q27473222 |
| | Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan Sulfate Interaction | Q27477606 |
| | Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells | Q27478383 |
| | Human Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture | Q27485012 |
| | Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein | Q27485318 |
| | Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor | Q27485871 |
| | CD81 Is a Central Regulator of Cellular Events Required for Hepatitis C Virus Infection of Human Hepatocytes | Q27486789 |
| | Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies | Q27487399 |
| | The Tight Junction-Associated Protein Occludin Is Required for a Postbinding Step in Hepatitis C Virus Entry and Infection | Q27488990 |
| | Human occludin is a hepatitis C virus entry factor required for infection of mouse cells | Q27490169 |
| | Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor | Q27490234 |
| | Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants | Q27490535 |
| | A broad-spectrum antiviral targeting entry of enveloped viruses | Q27491286 |
| | Hepatitis C Virus E2 Envelope Glycoprotein Core Structure | Q27680704 |
| | Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2 | Q27681839 |
| | Genetic organization and diversity of the hepatitis C virus | Q27860507 |
| | CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells | Q28114859 |
| | Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry | Q28131832 |
| | A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry | Q28475468 |
| | Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents | Q28538891 |
| | Claudin association with CD81 defines hepatitis C virus entry. | Q29465808 |
| | Hepatitis C virus induces CD81 and claudin-1 endocytosis | Q30512696 |
| | Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission | Q30541733 |
| | A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry | Q33531362 |
| | Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation | Q34096483 |
| | A human claudin-1-derived peptide inhibits hepatitis C virus entry | Q34179353 |
| | Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells | Q34182524 |
| | Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses | Q34182763 |
| | Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. | Q34194575 |
| | Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor | Q34245963 |
| | Development of oleanane-type triterpenes as a new class of HCV entry inhibitors | Q34344013 |
| | Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. | Q34470890 |
| | Different anti-HCV profiles of statins and their potential for combination therapy with interferon | Q34541863 |
| | Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes | Q34636137 |
| | Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking | Q34652154 |
| | In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus | Q34816677 |
| | Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. | Q34860505 |
| | Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. | Q35135565 |
| | Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E | Q35153978 |
| | Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans | Q35488198 |
| | Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo | Q39912694 |
| | Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. | Q40052203 |
| | Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain | Q40096322 |
| | The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles | Q40141383 |
| | Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding | Q40296319 |
| | Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes | Q40364883 |
| | Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis | Q40908899 |
| | Low density lipoprotein receptor as a candidate receptor for hepatitis C virus | Q40972546 |
| | Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes | Q40994676 |
| | Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice | Q41033867 |
| | Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry | Q41086265 |
| | A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans | Q42220929 |
| | Curing chronic hepatitis C--the arc of a medical triumph | Q42225548 |
| | HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. | Q42990165 |
| | Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes | Q42999009 |
| | The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. | Q43034249 |
| | Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model | Q35488854 |
| | Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody | Q35602284 |
| | A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo | Q35685409 |
| | Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells | Q35695028 |
| | Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. | Q35739094 |
| | Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. | Q35828072 |
| | Broad-spectrum antivirals against viral fusion | Q36010083 |
| | Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus Entry. | Q36080785 |
| | Identification of transferrin receptor 1 as a hepatitis C virus entry factor | Q36967731 |
| | Global control of hepatitis C: where challenge meets opportunity | Q37077112 |
| | EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy | Q37609988 |
| | Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies | Q37629584 |
| | Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. | Q37864742 |
| | Entry inhibitors and future treatment of hepatitis C. | Q38187814 |
| | Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate | Q38352468 |
| | Treatment of hepatitis C in difficult-to-treat patients | Q38431523 |
| | HCV targeting of patients with cirrhosis | Q38534820 |
| | Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry | Q38849121 |
| | Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action | Q38850319 |
| | Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus | Q38915788 |
| | Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry | Q38934862 |
| | Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections | Q38951860 |
| | Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus | Q38975650 |
| | Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes | Q38994889 |
| | Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly | Q39068693 |
| | A small-molecule inhibitor of hepatitis C virus infectivity | Q39069509 |
| | Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking | Q39104403 |
| | Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells | Q39117420 |
| | The antimalarial ferroquine is an inhibitor of hepatitis C virus. | Q39205134 |
| | Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate | Q39358973 |
| | (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry | Q39439105 |
| | The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry | Q39491188 |
| | Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors | Q39646696 |
| | 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses | Q39788993 |
| P433 | issue | 5 | |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P304 | page(s) | 741-748 | |
| P577 | publication date | 2016-04-05 | |
| P1433 | published in | Hepatology international | Q26842730 |
| P1476 | title | Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals | |
| P478 | volume | 10 | |